Navigation Links
Study finds new vulnerability in malaria parasite
Date:11/27/2013

NEW YORK, NY (November 27, 2013) An international team of scientists, including researchers at Columbia University Medical Center (CUMC), has identified a key metabolic enzyme that common malaria parasites require for survival at each stage of infection in humans. The findings raise the possibility of a new approach to combating malaria, one of the world's deadliest diseases. The study was published today in the online edition of the journal Nature.

"Perhaps the most exciting aspect of our findings is that this enzyme is required at all stages of the parasites' life cycle in humans," said co-first author Marcus C.S. Lee, PhD, associate research scientist in microbiology & immunology at CUMC. "This is important because most antimalarials are effective at killing the parasites only as they circulate in the bloodstream. However, the parasites can hide in the liver for years before reemerging and triggering a relapse of the disease. By identifying this enzyme, we may be able to develop a new way to kill the parasites in their dormant stage."

The other co-first author is Case W. McNamara, PhD, research investigator at the Genomics Institute for the Novartis Research Foundation. The study leaders are Elizabeth A. Winzeler, PhD, professor of pharmacology and drug discovery at University of California San Diego, and Thierry Diagana, head of Novartis Institute for Tropical Diseases in Singapore.

The enzyme phosphatidylinositol 4-kinase (PI4K) was found by screening more than a million drug compounds against Plasmodium falciparum, the parasite responsible for the most lethal form of malaria. Using this screen, the researchers found a class of compounds known as imidazopyrazines, which are capable of killing several species of Plasmodium at each stage of the parasites' life cycle in its vertebrate host. Also important, the compounds had no effect on human cells.

The researchers identified the target of the imidazopyrazines by evolving parasite cell lines that were resistant against the drugs and then analyzing the parasites' genomes for the changes responsible for conferring resistance. Those genetic changes pointed to the gene that encodes PI4K.

The CUMC team, led by David Fidock, PhD, professor of microbiology & immunology and medical sciences (in medicine), used novel genetic tools to confirm that PI4K was being directly targeted by the imidazopyrazines.

Then, using cellular imaging, the CUMC team found that imidazopyrazines interfere with the function of PI4K on the parasite Golgi (the organelle that packages proteins for delivery to other cellular destinations). "We think that disrupting the function of PI4K at the Golgi stops the parasite from making new membranes around its daughter cells, thereby preventing the organism from reproducing," said Dr. Lee.

Because PI4K is also found in humans, Dr. Winzeler said, the next challenge is to develop a drug that retains selectivity between the parasite and human versions of the enzyme. "As we now know the identity of this protein and hope to soon solve its structure, this task should be much easier," she said.


'/>"/>

Contact: Karin Eskenazi
ket2116@columbia.edu
212-342-0508
Columbia University Medical Center
Source:Eurekalert  

Related biology news :

1. Study finds the forgotten ape threatened by human activity and forest loss
2. Large study shows pollution impact on coral reefs -- and offers solution
3. CSI-type study identifies snakehead
4. Study examines potential evolutionary role of sexual regret in human survival and reproduction
5. Gene-silencing study finds new targets for Parkinsons disease
6. New genomic study provides a glimpse of how whales could adapt to ocean
7. Study finds gene network associated with alcohol dependence
8. A study on cell migration provides insights into the movement of cancer cells
9. UT Dallas study: Initial success for new tinnitus treatment
10. Connections in the brains of young children strengthen during sleep, CU-Boulder study finds
11. Women prescribed combination HRT should use caution when taking apigenin supplement, MU study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study finds new vulnerability in malaria parasite
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
Breaking Biology News(10 mins):
(Date:9/22/2017)... ... 22, 2017 , ... The Academy of Model Aeronautics (AMA) ... 29, 2017, to promote AMA’s programs, member services, and the model aviation hobby. ... but not limited to model aviation and other RC activities. , Thousands are ...
(Date:9/21/2017)... MA (PRWEB) , ... September 21, 2017 , ... ... proprietary clinical client portal. Each relaunch of the portal includes new features that ... and medical device companies seek to remain at the forefront of medical advancements, ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... technology, today announced the election of Paul Hermes, Entrepreneur in Residence at Medtronic, ... , Biorez has developed a proprietary, tissue-engineered scaffold for anterior cruciate ligament (ACL) ...
(Date:9/20/2017)... ... September 20, 2017 , ... Proscia Inc. , a ... provider of whole slide imaging solutions, are hosting a pre-conference workshop at the ... Deploying a Best-in-Class Strategy for Digital Pathology,” will feature Proscia CEO, David West ...
Breaking Biology Technology: